Advanced search

Vol 24, No 2 (2021)
Review paper
Published online: 2021-07-30

open access

View PDF Download PDF file
Page views 7520
Article views/downloads 1400
Get Citation

Connect on Social Media

Connect on Social Media

The role of [18F]FDG PET/CT for gastric cancer management

Ebru Salmanoglu1
DOI: 10.5603/NMR.2021.0021
Pubmed: 34382674
Nucl. Med. Rev 2021;24(2):99-103.

Abstract

Gastric cancer (GC) is a common cause of cancer-related deaths in the world. In addition to the patient’s clinical history and clinical examination, nuclear medicine tools are required for diagnosis. [18F]FDG PET/CT has been commonly used for cancer patients for staging, restaging, evaluation of treatment response. This study aimed to review the current literature on the role of [18F]FDG PET/CT for GC management.

Keywords: gastric cancerPET/CT[18F]FDG

Article available in PDF format

View PDF Download PDF file

References

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
    CrossRefPubMed
  2. Ajani JA, D'Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016; 14(10): 1286–1312.
    CrossRefPubMed
  3. Minamimoto R, Senda M, Jinnouchi S, et al. Performance profile of a FDG-PET cancer screening program for detecting gastric cancer: results from a nationwide Japanese survey. Jpn J Radiol. 2014; 32(5): 253–259.
    CrossRefPubMed
  4. Cui J, Zhao P, Ren Z, et al. Evaluation of dual time point imaging 18F-FDG PET/CT in differentiating malignancy from benign gastric disease. Medicine (Baltimore). 2015; 94(33): e1356.
    CrossRefPubMed
  5. Ma Q, Xin J, Zhao Z, et al. Value of ¹⁸F-FDG PET/CT in the diagnosis of primary gastric cancer via stomach distension. Eur J Radiol. 2013; 82(6): e302–e306.
    CrossRefPubMed
  6. Choi JY, Shim KN, Kim SE, et al. The clinical value of 18F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography for predicting regional lymph node metastasis and non-curative surgery in primary gastric carcinoma. Korean J Gastroenterol. 2014; 64(6): 340–347.
    CrossRefPubMed
  7. Kim HW, Won KS, Song BI, et al. Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer. Nucl Med Mol Imaging. 2015; 49(2): 135–142.
    CrossRefPubMed
  8. Lee SJ, Lee WW, Yoon HJ, et al. Regional PET/CT after water gastric inflation for evaluating loco-regional disease of gastric cancer. Eur J Radiol. 2013; 82(6): 935–942.
    CrossRefPubMed
  9. Kim J, Lim ST, Na CJ, et al. Pretreatment F-18 FDG PET/CT parameters to evaluate progression-free survival in gastric cancer. Nucl Med Mol Imaging. 2014; 48(1): 33–40.
    CrossRefPubMed
  10. Lee SY, Seo HJ, Kim S, et al. Prognostic significance of interim F-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer. Asia Pac J Clin Oncol. 2018; 14(5): e302–e309.
    CrossRefPubMed
  11. Song BI, Kim HW, Won KS, et al. Preoperative standardized uptake value of metastatic lymph nodes measured by 18F-FDG PET/CT improves the prediction of prognosis in gastric cancer. Medicine (Baltimore). 2015; 94(26): e1037.
    CrossRefPubMed
  12. Kwon HW, An L, Kwon HR, et al. Preoperative nodal F-FDG avidity rather than primary tumor avidity determines the prognosis of patients with advanced gastric cancer. J Gastric Cancer. 2018; 18(3): 218–229.
    CrossRefPubMed
  13. Kudou M, Kosuga T, Kubota T, et al. Value of preoperative PET-CT in the prediction of pathological stage of gastric cancer. Ann Surg Oncol. 2018; 25(6): 1633–1639.
    CrossRefPubMed
  14. Serrano OK, Love C, Goldman I, et al. The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review. J Surg Oncol. 2016; 113(6): 640–646.
    CrossRefPubMed
  15. Coupe NA, Karikios D, Chong S, et al. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. Ann Nucl Med. 2014; 28(2): 128–135.
    CrossRefPubMed
  16. Namikawa T, Okabayshi T, Nogami M, et al. Assessment of (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer. Int J Clin Oncol. 2014; 19(4): 649–655.
    CrossRefPubMed
  17. Findlay JM, Antonowicz S, Segaran A, et al. Routinely staging gastric cancer with F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. Eur Radiol. 2019; 29(5): 2490–2498.
    CrossRefPubMed
  18. Wang X, Wei Y, Xue Y, et al. Predictive role of the number of 18f-fdg-positive lymph nodes detected by PET/CT for pre-treatment evaluation of locally advanced gastric cancer. PLoS One. 2016; 11(12): e0166836.
    CrossRefPubMed
  19. Altini C, Niccoli Asabella A, Di Palo A, et al. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. Medicine (Baltimore). 2015; 94(20): e864.
    CrossRefPubMed
  20. Kaneko Y, Murray WK, Link E, et al. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med. 2015; 56(4): 523–529.
    CrossRefPubMed
  21. Kawanaka Y, Kitajima K, Fukushima K, et al. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT. Eur J Radiol. 2016; 85(5): 989–995.
    CrossRefPubMed
  22. Chung HW, Kim JH, Sung IK, et al. FDG PET/CT to predict the curability of endoscopic resection for early gastric cancer. J Cancer Res Clin Oncol. 2019; 145(3): 759–764.
    CrossRefPubMed
  23. Lee JW, Lee SM, Son MW, et al. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection. Eur J Nucl Med Mol Imaging. 2016; 43(5): 881–888.
    CrossRefPubMed
  24. Lee DY, Lee CH, Seo MJ, et al. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients. Ann Nucl Med. 2014; 28(8): 789–795.
    CrossRefPubMed
  25. Kim JH, Heo SH, Kim JW, et al. Evaluation of recurrence in gastric carcinoma: Comparison of contrast-enhanced computed tomography and positron emission tomography/computed tomography. World J Gastroenterol. 2017; 23(35): 6448–6456.
    CrossRefPubMed
  26. Kim SJ, Cho YS, Moon SH, et al. Primary tumor ¹⁸F-FDG avidity affects the performance of ¹⁸F-FDG PET/CT for detecting gastric cancer recurrence. J Nucl Med. 2016; 57(4): 544–550.
    CrossRefPubMed
  27. Li P, Liu Q, Wang C, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis. Ann Nucl Med. 2016; 30(3): 179–187.
    CrossRefPubMed
  28. Wang C, Guo W, Zhou M, et al. The predictive and prognostic value of early metabolic response assessed by positron emission tomography in advanced gastric cancer treated with chemotherapy. Clin Cancer Res. 2016; 22(7): 1603–1610.
    CrossRefPubMed
  29. Schneider PM, Eshmuminov D, Rordorf T, et al. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC Cancer. 2018; 18(1): 548.
    CrossRefPubMed
  30. Giganti F, De Cobelli F, Canevari C, et al. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. J Magn Reson Imaging. 2014; 40(5): 1147–1157.
    CrossRefPubMed
  31. Park S, Ha S, Kwon HW, et al. Prospective evaluation of changes in tumor size and tumor metabolism in patients with advanced gastric cancer undergoing chemotherapy: association and clinical implication. J Nucl Med. 2017; 58(6): 899–904.
    CrossRefPubMed
  32. Chen R, Zhou X, Liu J, et al. Relationship between 18F-FDG PET/CT findings and HER2 expression in gastric cancer. J Nucl Med. 2016; 57(7): 1040–1044.
    CrossRefPubMed
  33. Laboissiere RS, Buzelin MA, Balabram D, et al. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol. 2015; 15: 157.
    CrossRefPubMed
  34. Park JS, Lee N, Beom SH, et al. The prognostic value of volume-based parameters using F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer. 2018; 21(2): 213–224.
    CrossRefPubMed
  35. Celli R, Colunga M, Patel N, et al. Metabolic signature on 18F-FDG PET/CT, HER2 status, and survival in gastric adenocarcinomas. J Nucl Med Technol. 2016; 44(4): 234–238.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note